The MEIP chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the MEIP chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The MEIP stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View MEIP Detailed Price Forecast - CNN Money||View MEIP Detailed Summary - Google Finance|
|View MEIP Detailed Summary - Yahoo! Finance||View MEIP Stock Research & Analysis - Zacks.com|
|View MEIP Trends & Analysis - Trade-Ideas||View MEIP Major Holders - Barrons|
|View MEIP Call Transcripts - NASDAQ||View MEIP Breaking News & Analysis - Seeking Alpha|
|View MEIP Annual Report - CompanySpotlight.com||View MEIP OTC Short Report - OTCShortReport.com|
|View MEIP Fundamentals - TradeKing||View MEIP SEC Filings - Bar Chart|
|View Historical Prices for MEIP - The WSJ||View Performance/Total Return for MEIP - Morningstar|
|View the Analyst Estimates for MEIP - MarketWatch||View the Earnings History for MEIP - CNBC|
|View the MEIP Earnings - StockMarketWatch||View MEIP Buy or Sell Recommendations - MacroAxis|
|View the MEIP Bullish Patterns - American Bulls||View MEIP Short Pain Metrics - ShortPainBot.com|
|View MEIP Stock Mentions - StockTwits||View MEIP Stock Mentions - PennyStockTweets|
|View MEIP Stock Mentions - Twitter||View MEIP Investment Forum News - Investor Hub|
|View MEIP Stock Mentions - Yahoo! Message Board||View MEIP Stock Mentions - Seeking Alpha|
|View Insider Transactions for MEIP - SECform4.com||View Insider Transactions for MEIP - Insider Cow|
|View MEIP Major Holdings Summary - CNBC||View Insider Disclosure for MEIP - OTC Markets|
|View Insider Transactions for MEIP - Yahoo! Finance||View Institutional Holdings for MEIP - NASDAQ|
|View MEIP Stock Insight & Charts - FinViz.com||View MEIP Investment Charts - StockCharts.com|
|View MEIP Stock Overview & Charts - BarChart||View MEIP User Generated Charts - Trading View|
Phase 2 Interim Data Evaluating the Combination of Pracinostat and Azacitidine in Patients with Myelodysplastic Syndrome Presented at the 2018 American Society of Hematology Annual Meeting
Posted on Monday December 03, 2018
The data demonstrate a 9% discontinuation rate due to adverse events, a substantially lower rate than observed in an earlier study, as well as an encouraging 36% complete response rate among patients receiving at least 6 cycles of treatment. The ongoing Phase 2 open-label study is evaluating a 45 mg dose of pracinostat in combination with azacitidine in order to improve safety/tolerability and retain patients in study longer than in an earlier Phase 2 study evaluating a 60 mg dose.
MEI Pharma Presents Clinical Data from Ongoing Phase 1b Study of ME-401 in Patients with Indolent B-Cell Malignancies at the 2018 American Society of Hematology Annual Meeting
Posted on Sunday December 02, 2018
SAN DIEGO, Dec. 2, 2018 /PRNewswire/ -- MEI Pharma, Inc. (MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that results from an ongoing Phase 1b study support the complementary potential of intermittent and continuous dosing schedules of ME-401, a selective phosphatidylinositol 3-kinase ("PI3K") delta inhibitor, to optimize the clinical risk-benefit ratio in patients with relapsed/refractory follicular lymphoma. The data announced today continue to support the rationale for MEI's planned Phase 2 study that evaluates both a continuous (CS) and intermittent (IS) dosing schedule of ME-401 as a means to enhance the drug candidate's clinical profile and thus potentially deliver improved benefits to patients. The Phase 2 study is expected to start around year-end and is intended to support MEI's accelerated approval registration strategy if successful.
MEI Pharma Presents Preclinical Data Demonstrating Voruciclib Synergistically Induces Apoptosis in Combination with Venetoclax in Acute Myeloid Leukemia Cells at the 2018 American Society of Hematology Annual Meeting
Posted on Saturday December 01, 2018
SAN DIEGO, Dec. 1, 2018 /PRNewswire/ -- MEI Pharma, Inc. (MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced preclinical data presented at the 2018 American Society of Hematology (ASH) annual meeting demonstrating that voruciclib, MEI's orally available CDK9 inhibitor, synergistically induced apoptosis at clinically relevant concentrations when combined with venetoclax (marketed as Venclexta®) in human derived acute myeloid leukemia (AML) cells lines and patient samples. Voruciclib is currently being evaluated in a Phase 1b dose ranging study in patients with B-cell malignancies.
Is MEI Pharma Inc’s (NASDAQ:MEIP) CEO Paid At A Competitive Rate?
Posted on Friday November 30, 2018
Dan Gold became the CEO of MEI Pharma Inc (NASDAQ:MEIP) in 2010. This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar